Using D-Galactose as a food supplement in Congenital Disorders of Glycosylation (CDG)

Using D-Galactose as a food supplement in Congenital Disorders of Glycosylation (CDG) - Using Galactose in CDG

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON44612

Enrollment

Registered

2017-12-07

Start date

2017-12-13

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CDG Congential Disorder of Glycosylation

Interventions

1The participant will remain on his/her regular diet and will be asked to ingest an oral galactose (simple milk sugar) supplement. The amount of galactose in the supplement will be not more than wha

Eligibility

Age

2 Years to 11 Years

Inclusion criteria

Inclusion criteria: Patient is younger than 21 years old Patient has a biochemically and genetically proven Congenital Disorders of Glycosylation. No galactose intake last 6 weeks

Exclusion criteria

Exclusion criteria: Patient has any of the following conditions: Aldolase B deficiency Galactosemia Hemolytic uremic syndrome Severe anemia Diagnosis of intellectual disability or developmental delay Galactose Intolerance

Design outcomes

Primary

Measure	Time frame
Efficacy: Change of glycosylation in blood (sialotransferrin isoforms)	—

Secondary

Measure	Time frame
Compliance intake of galactose	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)